It is among the top five players in domestic formulation and CDMO in India in terms of revenue,” he saidĪfter a strong run in the first seven months of 2021, analysts expect that the Indian primary market to see continued action in the rest of the year.īut they have word of caution for the investors. “Windlass Biotech is a domestic focused formulation and CDMO player. Malakar of Ashika Stock Broking said Devyani International and Windlass Biotech are his preferred picks among the four.ĭevyani International boasts of a superb franchise network of KFC, Pizza Hut and Costa Coffee and there is huge growth opportunity in the Indian QSR segment, he said. It has picked Krsnaa Diagnostics, Windlas Biotech and Exxaro Tiles in that order. Hem Securities has not come out with any report on Devyani International.
There has been a strong momentum in the primary market and all four issues are expected to witness solid interest from investors, said market watchers. The former will sell its shares in the Rs 448-460 price range, while the latter will sell its equity at Rs 118-120 apiece. Windlas Biotech (Rs 402 crore) and Exxaro Tiles (Rs 161 crore) are comparatively smaller issues. Krsnaa Diagnostics aims to raise over Rs 1,213 crore in a price band of Rs 933-954. Heggie said: “We plan to commercialise our next-generation AAV gene therapy platform for haemophilia B while we continue to deploy the capsid and manufacturing platform across our pipeline of novel indications.“From a long-term investment perspective, pick strong companies with business moat and the promoter's pedigree,” he added.Įchoing the similar views, Astha Jain of Hem Securities said: “One should look for the fundamentally strong companies with reasonable valuations, which have left something on the table for investors.”Īmong the four, Devyani International is the largest issue, eyeing to mop up Rs 1,838 crore in the price band of Rs 86-90.
Its proprietary split packaging technology and high performing capsid allows the company to target monogenic diseases and, in the future, potentially treat complex disease areas not currently targeted by gene therapy. Targeting the liver with its novel gene therapy platform enables Freeline to treat a wide range of chronic diseases. It has plans to grow rapidly across all territories. Data gleaned from trials involving the first cohort of 10 patients was promising, the company says.ĬEO Theresa Heggie said: “The feedback builds on previously reported data which suggest that FLT180a has the potential, using relatively low doses, to create durable FIX activity levels in the normal range in patients with severe Haemophilia B and provide a functional cure.”įreeline is headquartered at Stevenage Bioscience Catalyst and has operations in Germany and the US.
Ipos 4 gene series#
The company plans to offer 7.4 million American Depositary Shares at $16-$18 apiece.Įven hitting halfway up the range Freeline could clinch a market value of around $574m. The company's lead candidate, FLT180a, is an investigational gene therapy medicinal product candidate for the treatment of haemophilia B and is currently in a Phase 1/2 trial.įreeline closed a $120 million extended Series C financing in June 2020. The company’s stated aim is to transform the lives of patients suffering from inherited systemic debilitating diseases.
Freeline Therapeutics in Stevenage, which is developing gene therapies for rare diseases, is bidding to raise $125 million through an IPO on the US technology market NASDAQ.